Moreover, HER2 can be therapeutically targeted with a monoclonal antibody trastuzumab and a small molecule HER2/EGFR (epidermal growth factor receptor) inhibitor lapatinib in the treatment of HER2 overexpressing breast and gastric cancers 16. Here, ERBB2 is linked to gastric cancer.